Pipeline
We’re developing medicines to support healthy aging in senior cats. Our products are designed to target conserved mammalian pathways involved in age-related decline – with a focus on targets involved in sarcopenia, CKD and neurodegeneration.
Novel SOTA models
Leveraging novel algorithms designed by TCHC in the past few years (held under trade secret), we accelerate the design and analysis of therapeutics for age-related diseases. Earlier, less-advanced versions of our softwares have been published as open-source to be used by the broader scientific community in journals such as Cell & Nature family.
Big data
Any algorithmic advancement needs to be accompanied by useful, high-quality, large datasets. We collected and generated terabytes of novel omic data from diseased, healthy, young and elderly cats.
Clinical validation
Our early-stage datasets show our therapeutics are safe and ready for further studies. The clinical trials are approved by veterinary regulatory agencies and are expected to provide results in 2026.